Breaking News on Global Pharmaceutical Technology & Manufacturing

News in brief

Novartis to build biotech facility in Singapore


Related topics: Processing

Novartis will spend $500m on a new cell-culture based manufacturing facility in Singapore.

The new biologics plant, which is due to be operational by 2016, will be built next to a solid dose pharmaceutical production facility that Novartis set up at the Tuas Biomedical Park in 2005.

The plan is to handle clinical and commercial production of monoclonal antibody-based medicines for autoimmune, respiratory and oncology indications.

CEO Joe Jimenez said that: "We have chosen Singapore as strategic supply point as it offers a wide range of advantages due to its strong local biomedical presence and knowledge, skilled labour as well as proximity to growth markets in Asia." asked Novartis if the plant is different from the one it said it would build in 2007 , but the firm did not respond to the request for information.